News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides a financial overview of XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) through TradingView. It offers access to the company's financials, news, community insights, and technical analysis data. The page is designed for investors to research XTL Biopharmaceuticals Ltd.'s performance and segments.
Sharemaestro market context Price below Trend Line 52 weeks -54.5% · Next-week setup negative 33.4%This article provides the "Price to earnings forward" value for XTL Biopharmaceuticals Ltd. (TASE:XTLB). The content is minimal, appearing to be a data point or a placeholder within a larger financial data platform.
Sharemaestro market context Price below Trend Line 52 weeks -54.5% · Next-week setup negative 33.4%This article provides a risk assessment for X T L Biopharmaceuticals Ltd (XTLB), noting its current risk score of 1.36 and a beta value of 1.52. The beta suggests the stock is more volatile than the S&P 500, performing better in a rising market …
This article provides a financial overview of X T L Biopharmaceuticals Ltd (XTLB), detailing its stock performance, market capitalization, and various financial statements. It presents a comprehensive data dashboard for investors, organizing complex financial information into customizable views. Key financial indicators, including EPS, revenue, …
This article provides a detailed cash flow statement for X T L Biopharmaceuticals Ltd (XTLB), presenting quarterly and annual figures for operating, investing, and financing cash flows from FY2012Q1 to FY2016Q2. It also includes FAQs defining key cash flow metrics like operating cash flow, …
This article provides a technical analysis of X T L Biopharmaceuticals Ltd (XTLB), detailing its current price momentum, support and resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and moving …
This article provides the quarterly and annual income statements for X T L Biopharmaceuticals Ltd (XTLB), detailing financial performance metrics such as revenue, operating expenses, and net income. It also includes an FAQ section explaining how to read the income statement and defining key …
This article provides a valuation analysis of X T L Biopharmaceuticals Ltd (XTLB), noting its current valuation score of 9.97, which ranks it highly within the Biotechnology & Medical Research industry. The company's P/E ratio is reported as -4.02. Key valuation metrics like P/B …
This article provides a revenue breakdown for XTL Biopharmaceuticals Ltd. Sponsored ADR (FWB:HHB0) on TradingView. It appears to be a stub or a placeholder page, as no actual financial data or detailed revenue information is presented, only navigation elements and a general overview of …
The article provides a historical overview of dividends and stock splits for X T L Biopharmaceuticals Ltd (XTLB). It indicates that the company has not distributed any dividends in the past five years. However, it lists two upcoming merger-related stock splits with a 4:1 …
The article details the shareholder structure of X T L Biopharmaceuticals Ltd (XTLB), outlining major individual and institutional holdings. Key individuals like Alexander Rabinovitch, Roy Klinger, Tal Klinger, and Yaron Yaacobi hold significant stakes, alongside various institutional types such as individual investors, hedge funds, …
XTL Biopharmaceuticals (XTLB) has regained compliance with Nasdaq listing rules, including public interest, periodic filing, bid price, and equity requirements, following its Form 20-F filing for fiscal 2025 and a sustained bid price above $1.00. The company also strengthened its equity through the acquisition …
Sharemaestro market context Price below Trend Line 52 weeks -54.5% · Next-week setup negative 33.4%XTL Biopharmaceuticals (XTLB) has regained compliance with Nasdaq's listing standards, including the Bid Price Rule, Periodic Filing Rule, Public Interest Concern Rule, and Equity Rule. This compliance was achieved by maintaining a bid price above $1.00 for 20 consecutive days, filing its 20-F, and …
Search by ticker symbol or company name and select a result to open its chart.